Eisai/Biogen’s Leqembi Sees Clear Path To Regular Approval For Alzheimer’s Disease

 
• By Sue Sutter
Clear path
The path from accelerated to traditional approval appears clear for Leqembi. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers